The Rise of GLP-1 Support Products at SupplySide Global 2025

At the SupplySide Global 2025 event, GLP-1 (glucagon-like peptide-1) emerged as a significant trend, reflecting a growing interest in both pharmaceutical and non-pharmaceutical solutions for weight management. Dominik Mattern, vice president of marketing at Balchem, noted that between 30 to 50 million people in the U.S. may be potential users of GLP-1 drugs, which have gained popularity due to their convenience in appetite suppression through injections. This shift marks a departure from traditional weight management strategies that relied on behavioral changes.

Nutritional Outlook

While GLP-1 medications offer benefits, they also present challenges, including reduced appetite and potential nutritional deficiencies. Ernest DeFreitas from Univar Solutions highlighted that users often experience dehydration and early satiety, necessitating a focus on nutritional support. Products designed to address these issues, such as hydration solutions, protein supplements, and functional foods, are increasingly important. Mattern emphasized the need for dietary supplements to bridge nutrient gaps exacerbated by GLP-1 usage, particularly in maintaining muscle mass during rapid weight loss.

Nutritional Outlook

Ingredient manufacturers are exploring natural alternatives to GLP-1 drugs. Rousselot's Nextida GC, a collagen peptide, has shown promise in increasing GLP-1 secretion, which can aid in weight management. Florencia Moreno Torres explained that taking Nextida GC before meals can significantly reduce post-meal sugar spikes, thereby minimizing subsequent sugar crashes that lead to cravings and overeating.

Nutritional Outlook

Another notable ingredient is Eriomin, a citrus flavonoid from Ingredients by Nature, which has been shown to elevate GLP-1 levels and improve blood glucose control. Doug Lynch, commercial lead for Ingredients by Nature, discussed its potential as an adjunct to medications like metformin, particularly for individuals experiencing metabolic distress.

Nutritional Outlook

Saanroo's Trpti, an Oleoylethanolamide (OEA) ingredient, represents another innovative approach to enhancing GLP-1 levels. Ramaswamy Venkatesh explained that OEA is naturally produced in response to feeding and plays a crucial role in GLP-1 release. However, factors such as aging and poor diet can disrupt OEA production, leading to impaired glucose tolerance and obesity. Clinical studies have demonstrated that Trpti can effectively increase GLP-1 levels while reducing DPP-4, an enzyme that degrades GLP-1.

Nutritional Outlook

Industry leaders are optimistic about the future of GLP-1 support products. Mattern noted the dual focus on nutrition support for GLP-1 users and the development of innovative products that naturally enhance GLP-1 production. The consensus among experts is that as demand for these solutions grows, further innovations will emerge to support consumers navigating the complexities of GLP-1 medications.

Nutritional Outlook

Despite the enthusiasm surrounding GLP-1 products, some experts caution against over-reliance on supplements as substitutes for comprehensive dietary changes. Critics argue that while these products can provide support, they should not replace the fundamental principles of balanced nutrition and lifestyle modifications.

Nutritional Outlook

“GLP-1 medicines have dramatically changed how millions of people experience food and beverages,” — Ernest DeFreitas, Senior Sales Director, Univar Solutions

Nutritional Outlook

“What you're doing is giving back to your body what it does best in a bioavailable form.” — Ramaswamy Venkatesh, Managing Director, Saanroo

Nutritional Outlook